Among the growth hormone secretagogues studied in preclinical research, Ipamorelin stands out for its exceptional receptor selectivity. Unlike earlier GH-releasing peptides, Ipamorelin stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels in cell-based assays — a profile that has made it one of the most widely used tools for studying the somatotropic axis in isolation.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective agonist of the ghrelin receptor (GHS-R1a). Developed in the 1990s, it was among the first GH secretagogues to demonstrate high GH-releasing potency combined with a clean side-effect profile in preclinical models, distinguishing it from earlier compounds like GHRP-2 and GHRP-6.
Key Areas of In Vitro Research
Ghrelin Receptor (GHS-R1a) Binding and Selectivity
In vitro binding studies have characterized Ipamorelin’s high affinity and selectivity for the GHS-R1a receptor. Radioligand binding assays have demonstrated its potent displacement of ghrelin at the receptor, while functional assays in pituitary cell lines have confirmed robust GH secretion with minimal activation of off-target receptors. This selectivity profile makes Ipamorelin a preferred tool for receptor pharmacology research.
GH Axis Stimulation Without Cortisol Elevation
A defining characteristic of Ipamorelin in preclinical research is its ability to stimulate GH release without triggering ACTH or cortisol secretion — a limitation of earlier GHRPs. In vitro studies using pituitary and adrenal cell line models have confirmed this selectivity, making Ipamorelin valuable for researchers who need to study GH axis activation in isolation from HPA axis confounders.
IGF-1 Downstream Signaling
Research has examined Ipamorelin’s downstream effects on IGF-1 expression in hepatocyte and muscle cell models. In vitro studies have demonstrated that GHS-R1a activation by Ipamorelin leads to measurable increases in IGF-1 mRNA expression, providing a cellular model for studying the GH/IGF-1 axis and its anabolic signaling cascades.
Synergistic Research with CJC-1295
Ipamorelin is frequently studied in combination with CJC-1295 (no DAC) to investigate dual-pathway GH axis activation. The IPAM + CJC no DAC blend available from Everlast Research provides researchers with a pre-formulated tool for studying the additive effects of simultaneous GHRH receptor and ghrelin receptor activation in cell culture models.
Ipamorelin at Everlast Research
Everlast Research supplies Ipamorelin as a high-purity (≥98% HPLC verified) lyophilized powder in 10mg quantities. It is also available in combination blends: IPAM + CJC no DAC and IPAM + TESA (with Tesamorelin) for multi-pathway research designs.
Research Compliance Note
All Ipamorelin products from Everlast Research are strictly for in vitro laboratory research use only. Not for human or veterinary use. Use only in certified laboratory environments under proper compliance.
Everlast Research supplies high-purity lyophilized research compounds for qualified laboratory professionals. All products are for in vitro research use only.